{"id":"https://openalex.org/W2678736760","doi":null,"title":"Clinical Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase 1 Inhibitor","display_name":"Clinical Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase 1 Inhibitor","alternate_titles":[],"publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2678736760","mag":"2678736760"},"language":"en","primary_location":{"id":"mag:2678736760","doi":null,"is_oa":false,"landing_page_url":"https://oak.novartis.com/32234/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2678736760"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100457146","display_name":"Jin Chen","orcid":"https://orcid.org/0000-0001-7617-1664","observed_orcids":["https://orcid.org/0000-0001-7617-1664"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jin Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7617-1664","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030823772","display_name":"Charles Daniel Meyers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Charles D. Meyers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044170245","display_name":"Debbi Keefe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Debbi Keefe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084146690","display_name":"Jing Yu","orcid":"https://orcid.org/0009-0008-7692-9816","observed_orcids":["https://orcid.org/0009-0008-7692-9816"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jing Yu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-7692-9816","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5031520819","display_name":"Gangadhar Sunkara","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gangadhar Sunkara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1905,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.52176797,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":92},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/familial-chylomicronemia-syndrome","display_name":"familial chylomicronemia syndrome","score":0.9940000176429749},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/lipoprotein-lipase-deficiency","display_name":"lipoprotein lipase deficiency","score":0.9629999995231628},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8299999833106995},{"id":"https://openalex.org/keywords/glucuronidation","display_name":"glucuronidation","score":0.8379999995231628},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.8429999947547913},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.9760000109672546},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.968999981880188},{"id":"https://openalex.org/keywords/qtc-interval","display_name":"QTc interval","score":0.6330000162124634},{"id":"https://openalex.org/keywords/photosensitivity","display_name":"photosensitivity","score":0.8539999723434448},{"id":"https://openalex.org/keywords/triglyceride-lowering","display_name":"triglyceride lowering","score":0.5299999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6223501563072205},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6140577793121338},{"id":"https://openalex.org/C2780213950","wikidata":"https://www.wikidata.org/wiki/Q908765","display_name":"Hepatic lipase","level":4,"score":0.5723154544830322},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5217298269271851},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5053156018257141},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4704752564430237},{"id":"https://openalex.org/C2776919658","wikidata":"https://www.wikidata.org/wiki/Q1467339","display_name":"Hypertriglyceridemia","level":4,"score":0.4566267430782318},{"id":"https://openalex.org/C11772777","wikidata":"https://www.wikidata.org/wiki/Q423126","display_name":"Chylomicron","level":5,"score":0.45414069294929504},{"id":"https://openalex.org/C2778620825","wikidata":"https://www.wikidata.org/wiki/Q1344633","display_name":"Enterohepatic circulation","level":3,"score":0.43634453415870667},{"id":"https://openalex.org/C2778697171","wikidata":"https://www.wikidata.org/wiki/Q418006","display_name":"Cholestyramine","level":3,"score":0.42838728427886963},{"id":"https://openalex.org/C2779120738","wikidata":"https://www.wikidata.org/wiki/Q2711291","display_name":"Familial hypercholesterolemia","level":3,"score":0.4140487611293793},{"id":"https://openalex.org/C2778913445","wikidata":"https://www.wikidata.org/wiki/Q186319","display_name":"Triglyceride","level":3,"score":0.361805260181427},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.26025211811065674},{"id":"https://openalex.org/C8243546","wikidata":"https://www.wikidata.org/wiki/Q419074","display_name":"Very low-density lipoprotein","level":4,"score":0.2224113643169403},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.21562451124191284},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2678736760","doi":null,"is_oa":false,"landing_page_url":"https://oak.novartis.com/32234/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2130127759","https://openalex.org/W2052570374","https://openalex.org/W1976951234","https://openalex.org/W2124311778","https://openalex.org/W2196672055","https://openalex.org/W2950104557","https://openalex.org/W2142461696","https://openalex.org/W2201954606","https://openalex.org/W2081142641","https://openalex.org/W3198137402"],"abstract_inverted_index":{"Background:":[0],"Familial":[1],"chylomicronemia":[2],"syndrome":[3],"(FCS)":[4],"is":[5,38,85,97,183,217,228],"a":[6,22],"rare":[7],"lipid":[8],"disease":[9],"resulting":[10],"in":[11,52,99,110,120,129,168,179,197,219],"severe":[12,113],"hypertriglyceridemia":[13],"caused":[14],"by":[15,88],"complete":[16],"lipoprotein":[17],"lipase":[18],"(LPL)":[19],"deficiency.":[20],"Pradigastat,":[21],"highly":[23],"potent":[24],"and":[25,54,68,94,96,128,140,150,166,191,224],"specific":[26],"diacylglycerol":[27],"acyltransferase":[28],"1":[29],"(DGAT1)":[30],"inhibitor":[31],"that":[32],"blocks":[33],"chylomicron":[34],"triglyceride":[35],"(TG)":[36],"synthesis,":[37],"an":[39],"attractive":[40],"therapy":[41],"for":[42,230],"patients":[43,111,121,130,231],"with":[44,112,122,131,144,188,232,239],"FCS.":[45],"\r\n\r\nObjective:":[46],"To":[47],"summarize":[48],"the":[49,102,176,200],"data":[50],"from":[51],"vitro":[53],"clinical":[55,202],"pharmacokinetic":[56],"studies":[57],"of":[58,107,204,221],"pradigastat.":[59],"\r\n\r\nResults:":[60],"Following":[61],"oral":[62,151],"administration,":[63],"pradigastat":[64,76,108],"was":[65],"slowly":[66,69],"absorbed":[67],"eliminated.":[70],"Food":[71],"intake":[72],"does":[73,193],"not":[74,118,194],"impact":[75],"exposure":[77,106],"to":[78,124,234],"any":[79],"clinically":[80],"relevant":[81],"extent.":[82],"Pradigastat":[84,134,153,171,208],"primarily":[86],"metabolized":[87],"hepatic":[89,114,126,236],"glucuronosyltransferase":[90],"(UGT)":[91],"enzymes":[92],"UGT1A1":[93],"UGT1A3,":[95],"eliminated":[98],"feces":[100],"through":[101],"biliary":[103],"pathway.":[104],"The":[105],"doubled":[109],"impairment":[115,127,237],"but":[116],"did":[117],"change":[119],"mild":[123,233],"moderate":[125,235],"renal":[132,240],"impairment.":[133,241],"has":[135,172],"low":[136],"drug-drug":[137,222],"interaction":[138,143],"potential":[139],"had":[141],"no":[142,173,184,225],"atazanavir,":[145],"probenecid,":[146],"rosuvastatin,":[147],"digoxin,":[148],"warfarin,":[149],"contraceptives.":[152],"substantially":[154],"reduces":[155],"plasma":[156],"fasting":[157],"TG":[158],"levels":[159],"(70%":[160],"at":[161,199],"40":[162,205],"mg),":[163],"post-prandial":[164],"TG,":[165],"apo48":[167],"FCS":[169],"patients.":[170],"effect":[174],"on":[175],"QTc":[177,190],"interval":[178],"humans,":[180],"hence":[181],"there":[182],"dysrhythmia":[185],"risk":[186],"associated":[187],"prolonged":[189],"it":[192],"induce":[195],"photosensitivity":[196],"humans":[198],"highest":[201],"dose":[203,215,226],"mg.":[206],"\r\n\r\nConclusion:":[207],"can":[209],"be":[210],"taken":[211],"without":[212],"food.":[213],"No":[214],"adjustment":[216,227],"needed":[218,229],"consideration":[220],"interaction,":[223],"or":[238]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2678736760","counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2017-06-30T00:00:00"}
